These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 19871154)

  • 21. STUDIES ON THE BIOLOGY OF STREPTOCOCCUS : IV. THE OCCURRENCE OF STREPTOCOCCUS SCARLATINAE IN CONVALESCENCE AND IN THE COMPLICATIONS OF SCARLET FEVER.
    Stevens FA; Dochez AR
    J Exp Med; 1924 Sep; 40(4):493-501. PubMed ID: 19868935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. THE PYROGENIC EFFECT OF SCARLET FEVER TOXIN. I. NEUTRALIZATION WITH ANTITOXIN; THE NATURE OF TOLERANCE.
    SCHUH V
    Folia Microbiol (Praha); 1965 May; 10():156-62. PubMed ID: 14344773
    [No Abstract]   [Full Text] [Related]  

  • 23. [Comparative studies on the qualitative significance of the flocculation reaction with Hayem's solution (after Gros) and blood sedimentation velocity (after Westergren) in scarlet fever].
    WIESNER H
    Z Gesamte Inn Med; 1951 Mar; 6(5-6):138-42. PubMed ID: 14836904
    [No Abstract]   [Full Text] [Related]  

  • 24. Host-parasite factors in group A streptococcal infections. Pyrogenic and other effects of immunologic distinct exotoxins related to scarlet fever toxins.
    WATSON DW
    J Exp Med; 1960 Feb; 111(2):255-84. PubMed ID: 13783427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STUDIES IN SCARLET FEVER: I. The Amount of Scarlatinal Toxin in the Blood of Patients with Scarlet Fever.
    Trask JD
    J Clin Invest; 1926 Dec; 3(2):391-6. PubMed ID: 16693721
    [No Abstract]   [Full Text] [Related]  

  • 26. Modern trends in the treatment of scarlet fever.
    McLACHLAN IM
    Med Press; 1951 Feb; 225(7):147-50. PubMed ID: 14805669
    [No Abstract]   [Full Text] [Related]  

  • 27. ACTIVE IMMUNITY PRODUCED BY SO CALLED BALANCED OR NEUTRAL MIXTURES OF DIPHTHERIA TOXIN AND ANTITOXIN.
    Smith T
    J Exp Med; 1909 Mar; 11(2):241-56. PubMed ID: 19867246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pyrogenic effect of scarlet fever toxin. 3. The effect of cortisone on the pyrogenic, lethal and dermal activity of scarlet fever toxin.
    Hríbalová V; Schuh V
    Folia Microbiol (Praha); 1967; 12(5):477-88. PubMed ID: 6056768
    [No Abstract]   [Full Text] [Related]  

  • 29. ETIOLOGY OF OROYA FEVER : II. VIABILITY OF BARTONELLA BACILLIFORMIS IN CULTURES AND IN THE PRESERVED BLOOD AND AN EXCISED NODULE OF MACACUS RHESUS.
    Noguchi H
    J Exp Med; 1926 Sep; 44(4):533-8. PubMed ID: 19869204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACTIVE IMMUNIZATION OF GUINEA PIGS WITH THE VIRUS OF EQUINE ENCEPHALOMYELITIS : IV. EFFECT OF IMMUNE SERUM ON ANTIGENICITY OF ACTIVE AND INACTIVE VIRUS.
    Cox HR; Olitsky PK
    J Exp Med; 1936 Jul; 64(2):223-32. PubMed ID: 19870532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scarlet Fever Epidemic in China Caused by Streptococcus pyogenes Serotype M12: Epidemiologic and Molecular Analysis.
    You Y; Davies MR; Protani M; McIntyre L; Walker MJ; Zhang J
    EBioMedicine; 2018 Feb; 28():128-135. PubMed ID: 29342444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STUDIES IN SCARLET FEVER: IV. Post-scarlatinal Immunity in Patients Treated with Antitoxin.
    Davies JA
    J Clin Invest; 1926 Dec; 3(2):423-33. PubMed ID: 16693724
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunochemical studies of antitoxin produced in normal and allergic individuals hyperimmunized with diphtheria toxoid. II. A comparison between the immunological properties of precipitating and non-precipitating (skin-sensitizing) antitoxins.
    KUHNS WJ; PAPPENHEIMER AM
    J Exp Med; 1952 Apr; 95(4):375-92. PubMed ID: 14938507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of low tetanus or diphtheria antitoxin titers in sera by a toxin neutralization assay and a modified toxin-binding inhibition test.
    Sonobe MH; Trezena AG; Guilhen FB; Takano VL; Fratelli F; Sakauchi D; Morais JF; Prado SM; Higashi HG
    Braz J Med Biol Res; 2007 Jan; 40(1):69-76. PubMed ID: 17224998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STUDIES ON THE BIOLOGY OF STREPTOCOCCUS : VI. BIOLOGY OF HEMOLYTIC STREPTOCOCCUS: ANTIGENIC RELATIONSHIPS BETWEEN STRAINS OF THE SCARLATINAL AND ERYSIPELAS GROUPS.
    Stevens FA; Dochez AR
    J Exp Med; 1926 Sep; 44(4):439-46. PubMed ID: 19869198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Etiological characteristics of
    Yin JY; Zhang W; Yang DJ; Li L; Dong XC
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Oct; 52(10):1045-1049. PubMed ID: 30392325
    [No Abstract]   [Full Text] [Related]  

  • 37. Combined estimation of tetanus and diphtheria antitoxin in human sera by the in vitro Toxin-Binding Inhibition (ToBI) test.
    Hendriksen CF; van der Gun JW; Kreeftenberg JG
    J Biol Stand; 1989 Apr; 17(2):191-200. PubMed ID: 2715153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Apropos of the kinetics of the flocculation of the diphteria toxin-antitoxin system].
    DEPELCHIN A; DIRKX J
    Rev Immunol Ther Antimicrob; 1962; 26():1-22. PubMed ID: 14027083
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of in vitro Vero cell assay and ELISA in the United States potency test of vaccines containing adsorbed diphtheria and tetanus toxoids.
    Gupta RK; Siber GR
    Dev Biol Stand; 1996; 86():207-15. PubMed ID: 8785950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Detection of scarlet fever antitoxin in the human serum with the aid of precipitation reaction].
    BACKHAUSZ R; KAMARAS J; OSZTOVICS M
    Gyermekgyogyaszat; 1954 Jan; 5(1):21-6. PubMed ID: 13151489
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.